Health Law Updates – May 23, 2012

by Andrew Weinstein on 5/23/2012

On May 04, 2012, Florida Governor Rick Scott signed legislation that was designed to reduce auto accident fraud, lower the cost of auto insurance premiums, and reduce the litigation costs associated with the current Personal...more

by James Dietz on 5/23/2012

Forty-three Roman Catholic institutions - including the University of Notre Dame - and 13 dioceses sued the Department of Health and Human Services (HHS) this week in an effort to halt the implementation of a rule requiring...more

by Ober|Kaler on 5/23/2012

In an April 6, 2012 Survey & Certification Letter (S&C: 12-26-HHA) [PDF] CMS reminded Home Health Agencies (HHAs) of the January 1, 2010 change in the process for an HHA to reactivate its billing privileges. Since the June...more

by Mintz Levin - Health Law on 5/22/2012

After two days of debate that featured consideration of 265 amendments, the Massachusetts Senate last week voted 35-2 to approve health care payment reform legislation. The Senate bill anticipates medical cost savings of $150...more

by Ober|Kaler on 5/22/2012

CMS has been busy addressing GME and IME issues in recent days. First, in late April, the agency issued its proposed Federal Fiscal Year 2013 inpatient prospective payment system (IPPS) update, which contains a number of...more

by McDermott Will & Emery on 5/22/2012

Effective May 30, 2012, a clinical investigator deemed ineligible to receive one type of test article (e.g., drug, device or new animal drug) due to repeated or deliberate violations of the U.S. Food and Drug Administration’s...more

by Reed Smith on 5/22/2012

Pharmaceuticals, Medical Devices, Health Care & Life Sciences News • NDRC: Chinese government to review carefully drug pricing differences between ex-factory and bid prices (NBD News 2012-04-05) – April 5, 2012...more

by King & Spalding on 5/21/2012

On May 9, 2012, the Office of Inspector General for the Department of Health & Human Services (OIG) issued a report addressing retail pharmacies identified as having questionable billing for Medicare Part D prescription drug...more